SOURCE: Streetwise Reports

Streetwise Reports

October 06, 2017 08:45 ET

Streetwise Reports Interviews CJ Partners' Colin Lee Novick Who Says Japan is Fertile Ground for Biotech Deals

SAN FRANCISCO, CA--(Marketwired - October 06, 2017) - Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness.

Included in this interview is: RepliCel Life Sciences Inc. (TSX VENTURE: RP) (OTCQB: REPCF)

The Life Sciences Report: Colin, would you bring us up to date on RepliCel Life Sciences Inc.'s trials?

Colin Lee Novick: From a biotech company's point of view, one of the important things is successfully meeting clinical trial endpoints. But from a biotech investor's point of view, what's oftentimes really important are the answers to the questions: When are you going to have your partner and where are you going to have that exit?

Both these questions were top-of-mind for RepliCel and its investors this year. Firstly, RepliCel successfully finished the clinical trials for RCS-01 and RCT-01, for tendon regeneration and skin rejuvenation, respectively. What followed is that these have fueled discussions with potential partners.

For instance, RepliCel had one clinical trial, Phase 1/2a, for tendon repair in chronic Achilles tendinosis on the RCT-01, a randomized 3:1, double-blind, placebo-controlled trial at the University of British Columbia Sports Medicine Clinic with eight participants. As for final results, the trial met its goal and established a complete safety profile at six months that showed no serious adverse events related to the study treatment or injection procedure. Usually, with the injection, you're going to get some mild irritation, but that's not a large safety issue. It allows RepliCel to proceed to the next stage.

Continue reading this interview: Japan Is Fertile Ground for Biotech Deals

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following companies mentioned in this interview are billboard sponsors of Streetwise Reports: RepliCel Life Sciences Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclaimers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer.

Please see the end of the article for the complete disclosures: Japan Is Fertile Ground for Biotech Deals

Contact Information

  • Contact Information:
    Carrie Beal Amaro
    Associate Publisher
    Email contact